Welcome back to BridgeWell Grand Rounds.
I am Dr. Sheri Erwin. This is Episode 3. The synthesis.
Over two episodes we worked through four upstream systems in Sarah's case.
The HPA axis. The gut and estrobolome. Metabolic signaling. And neuroinflammation.
We have a complete clinical picture.
Today I am going to show you how to bring that picture together into a sequenced intervention plan.
Because this is where systems-based reasoning either transforms a patient's outcome or falls apart.
It is not enough to identify the upstream drivers. You have to address them in the right order.
Get the sequencing wrong and you are still chasing symptoms.
Get it right and Sarah starts to genuinely respond. Not just briefly. Sustainably.
Let me bring the picture together before we talk about interventions.
System one. HPA axis. Flat cortisol diurnal curve. Morning cortisol at the low-normal end of the functional range. Depleted DHEA-S. Directly impairing progesterone receptor function and disrupting sleep architecture.
System two. Gut and estrobolome. Elevated zonulin indicating intestinal permeability. Positive LPS antibodies indicating bacterial endotoxin entering systemic circulation. Dysbiosis on organic acids. Estrobolome disruption altering how Sarah metabolizes and recirculates estrogen.
System three. Metabolic signaling. Fasting insulin at 14.2 with a HOMA-IR of 3.3. Triglyceride to HDL ratio at 2.8. Significant early insulin resistance invisible on standard metabolic panels.
System four. Neuroinflammation. Homocysteine elevated above functional target. Vitamin D insufficient. Magnesium RBC depleted. Systemic inflammatory markers present across multiple labs.
This is what was driving Sarah's non-response. Not the BHRT dose. The environment.
Here is the most important principle in treating a patient like Sarah.
You cannot layer interventions randomly. You have to work from the deepest driver outward.
If you start with the gut before you address the HPA axis, the cortisol burden will continue to drive intestinal permeability and undermine your gut work.
If you start with the hormones before you address the insulin resistance, the metabolic environment continues to disrupt hormone signaling.
Every intervention layer depends on the one beneath it being stable enough to allow it to work.
The sequence matters.
Phase one. HPA axis stabilization and systemic inflammation reduction. This is the foundation. Nothing else builds reliably until the cortisol burden is reduced and the inflammatory signal is addressed.
For the HPA axis.
Ashwagandha 300 to 600 milligrams nightly. The most evidence-supported adaptogen for HPA axis regulation and cortisol normalization.
Phosphatidylserine 200 to 400 milligrams daily. Randomized trial data showing blunted cortisol response to stress.
Magnesium glycinate 300 to 400 milligrams nightly. Supports HPA axis regulation and sleep architecture.
For systemic inflammation.
Vitamin D3 5000 to 10000 international units daily with Vitamin K2 MK-7 100 to 200 micrograms. Retest at 90 days. Target 50 to 70 nanograms per milliliter.
Omega-3 fatty acids 2 to 3 grams of EPA plus DHA daily.
Bioavailable curcumin 500 to 1000 milligrams daily.
And sleep hygiene is a clinical prescription at this stage. Not lifestyle advice.
Consistent wake time regardless of bedtime. No screens 90 minutes before sleep. Temperature regulation.
This is first-order intervention for HPA axis recovery. Not optional.
Phase two. Gut restoration. Once the HPA axis is partially stabilized and the inflammatory signal is reducing, the gut work has a foundation to build on.
Remove the drivers first.
If Sarah is using a PPI, that conversation needs to happen. Chronic PPI use is independently associated with significantly elevated SIBO risk and further disrupts gastric acid production.
A low-glycemic anti-inflammatory dietary shift is part of the protocol.
Gut barrier repair.
L-glutamine 5 grams twice daily on an empty stomach. Primary fuel source for intestinal enterocytes and a key substrate for tight junction repair.
Zinc carnosine 75 milligrams twice daily. Well-studied for gastric and intestinal mucosal repair.
Deglycyrrhizinated licorice before meals. Colostrum to support secretory IgA.
Microbiome restoration.
Multi-strain probiotic containing Lactobacillus acidophilus, Bifidobacterium longum, and Bifidobacterium infantis. Introduce prebiotic fiber gradually as symptoms allow.
Depending on the organic acids picture, a targeted antimicrobial protocol may be indicated for the yeast overgrowth pattern. Assess this at the four-week mark.
Phase three. Insulin resistance. With the HPA axis stabilizing and gut work underway, the metabolic layer can be addressed effectively.
Before this point the cortisol burden and gut inflammation were driving insulin resistance from the top down.
Now the metabolic intervention has a better chance of holding.
Dietary approach first. Low glycemic index. Time-restricted eating window of 8 to 10 hours. Protein-forward meal composition with minimum 1.2 grams per kilogram body weight daily.
Targeted supplementation.
Berberine 500 milligrams twice daily with meals. Titrate from 500 milligrams once daily to reduce gastrointestinal side effects. Multiple randomized controlled trials demonstrate berberine's effect on insulin sensitivity comparable to metformin.
Myo-inositol 2 grams plus D-chiro-inositol 200 to 400 milligrams daily.
Alpha lipoic acid 300 to 600 milligrams daily.
For the weight gain. Once insulin resistance is addressed, assess for BHRT dosing reassessment if indicated. The weight gain driven by insulin resistance will begin to resolve as metabolic function improves.
Do not increase the BHRT dose before this layer is addressed.
Phase four. Hormonal reassessment. At eight to twelve weeks, with three upstream layers addressed, the hormonal environment has fundamentally changed.
Now the BHRT conversation can be meaningful.
Recheck her cortisol pattern. Has the diurnal curve normalized.
Recheck her gut markers. Has the zonulin normalized. Is the LPS antibody picture improving.
Recheck her fasting insulin and HOMA-IR. Are they trending toward the functional target.
If those markers are improving, the question about her BHRT dosing becomes a different conversation.
She may need a dose adjustment now that the environment is no longer undermining the treatment.
Or she may find that the same dose that appeared inadequate is now working appropriately. Because the receptor environment has changed.
Do not assume the BHRT needs to change until the upstream work has had time to effect change in the environment.
The follow-up structure.
Four to six weeks after initiating phase one. Not three months. Four to six weeks.
Assess early response. Troubleshoot supplement tolerance. Determine readiness to add phase two.
At eight to twelve weeks a formal reassessment. Repeat the labs that were abnormal at baseline.
Cortisol. DHEA-S. Fasting insulin. HOMA-IR. Zonulin if available. High-sensitivity CRP. Homocysteine. Vitamin D.
The conversation about where to go next is data-driven.
This is the structure that turns a symptomatic patient into a patient who is genuinely responding.
Not because you found the right hormone dose. Because you addressed the environment the hormones are operating in.
Sarah is not a complicated case.
She is a common case. The NP on BHRT who is not responding. The patient with fatigue, weight gain, brain fog, and disrupted sleep whose conventional workup keeps coming back normal.
The complexity is not in the diagnosis. It is in the clinical reasoning required to look upstream from the presenting symptoms and find the actual drivers.
That is what systems-based medicine does.
And that is what BridgeWell teaches.
Thank you for following Sarah's case through all three episodes.
The clinical companion handouts for this series are at bridgewelled.com/case-series. Full lab reference tables with conventional and functional ranges for everything we covered. Free download. Go get them if you have not already.
And if this kind of clinical thinking is what you have been searching for, I want to invite you to book a Bridge Call. It is a free 30-minute conversation with me directly. You tell me where you are clinically and where you want to go. I give you an honest assessment of your best next step.
The link is in the episode description.
I am Dr. Sheri Erwin.
This has been BridgeWell Grand Rounds.
